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A R T I C L E I N F O
Meetings at which parts of the data were
presented: Week 96 data were presented in part
at ID Week, October 3–7, 2018, in San
Francisco, CA, USA (abstract 1768).
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A B S T R A C T
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10mg was investigated
through 96 weeks in EMERALD (NCT02269917).
Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic
failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus em-
tricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm
were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed
on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic re-
bound (PDVR; confirmed viral load [VL] ≥50 copies/mL) and VL < 50 copies/mL (virologic suppression) and
≥50 copies/mL (VF) (FDA-snapshot analysis).
Of 1141 randomized patients, 1080 continued in the extension phase. Few patients had PDVR (D/C/F/TAF:
3.1%, 24/763 cumulative through week 96; late-switch: 2.3%, 8/352 week 52–96). Week 96 virologic sup-
pression was 90.7% (692/763) (D/C/F/TAF) and 93.8% (330/352) (late-switch). VF was 1.2% and 1.7%, re-
spectively. No darunavir, primary PI, tenofovir or emtricitabine resistance-associated mutations were observed
post-baseline. No patients discontinued for efficacy-related reasons. Few discontinued due to adverse events (2%
D/C/F/TAF arm). Improved renal and bone parameters were maintained in the D/C/F/TAF arm and observed in
the late-switch arm, with small increases in total cholesterol/high-density-lipoprotein-cholesterol ratio. A study
limitation was the lack of a control arm in the week 96 analysis.
Through 96 weeks, D/C/F/TAF resulted in low PDVR rates, high virologic suppression rates, very few VFs,
and no resistance development. Late-switch results were consistent with D/C/F/TAF week 48 results. EMERALD
week 96 results confirm the efficacy, high genetic barrier to resistance and safety benefits of D/C/F/TAF.
1. Introduction
For long-term virologic success in the treatment of HIV-1 infection,
sustained efficacy, long-term safety, tolerability, a high genetic barrier
to resistance and convenience are important considerations, given the
prolonged time individuals will receive antiretroviral treatment (ART).
Since the approval of boosted darunavir (DRV) in 2006, a wealth of
clinical trial data and clinical experience has been generated, which
demonstrates its high, durable virologic response, high genetic barrier
to resistance, and long-term safety in a broad range of patients (Cahn
et al., 2011; Eron et al., 2018; Flynn et al., 2014; Lathouwers et al.,
2017; Orkin et al., 2013, 2018).
Once-daily, single-tablet HIV-1 treatment regimens (STRs) are pre-
ferred by patients and improve treatment adherence and satisfaction,
potentially reducing the rate of virologic failure (VF) and emergence of
antiretroviral resistance, resulting in a higher probability of long-term
viral load (VL) suppression, compared with multi-tablet regimens (Clay
et al., 2015; Nachega et al., 2011; Sterrantino et al., 2012). A once-
daily, STR combining darunavir with cobicistat, emtricitabine, and te-
nofovir alafenamide (D/C/F/TAF) 800/150/200/10mg, was recently
approved in the US, EU, and Canada (SYMTUZA™ tablets Summary of
Product Characteristics, 2017; Prescribing information for SYMTUZA™,
2018).
The primary 48-week analyses of the phase 3 AMBER
(NCT02431247) (Eron et al., 2018) and EMERALD (NCT02269917)
(Orkin et al., 2018) trials showed that D/C/F/TAF had high, non-in-
ferior antiviral efficacy with more favorable renal and bone safety
versus D/C plus emtricitabine/tenofovir disoproxil fumarate (F/TDF) in
ART-naïve adults in AMBER (Eron et al., 2018) and versus boosted
protease inhibitor (bPI) plus F/TDF in ART-experienced, virologically
suppressed adults in EMERALD (Orkin et al., 2018).
Treatment guidelines include the D/C/F/TAF STR or DRV boosted
with ritonavir or cobicistat combined with 2 nucleoside or nucleotide
analogs reverse transcriptase inhibitors (N(t)RTIs) as a recommended
treatment option (EACS, 2018) or recommend in certain clinical si-
tuations, such as for those patients who may have uncertain adherence,
those who require a regimen with a high genetic barrier to resistance,
or those patients who may not have resistance results available (Panel
on Antiretroviral Guidelines for Adults and Adolescents, updated July
10, 2019; Saag et al., 2018).
A predefined week 96 analysis of the efficacy and safety of D/C/F/
TAF in the EMERALD clinical trial is presented.
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2. Material and methods
2.1. Study design and patients
Detailed methods for EMERALD (TMC114IFD3013) have been
previously reported (Orkin et al., 2018). Briefly, EMERALD is a phase 3,
randomized, active-controlled, open-label, non-inferiority study con-
ducted at 106 sites across 9 countries. The study included ART-ex-
perienced, HIV-1-positive adults who were virologically suppressed
(VL < 50 copies/mL for≥ 2 months before screening; one VL 50–200
copies/mL within 12 months prior to screening was allowed) on stable
bPI (DRV/ritonavir or DRV/cobicistat once daily, atazanavir/ritonavir
or atazanavir/cobicistat once daily, or lopinavir/ritonavir twice daily)
plus F/TDF regimens for≥ 6 months. Previous non-DRV VF was al-
lowed. If historical genotypes were available, absence of DRV re-
sistance-associated mutations (RAMs) was required in line with the
DRV once daily indication.
The trial consisted of a 48-week treatment period during which
patients were randomized (2:1) to switch to the once daily D/C/F/TAF
800/150/200/10mg STR or continue on a bPI combined with F/TDF.
Patients could then continue on D/C/F/TAF (D/C/F/TAF arm) or
switch from bPI plus F/TDF to D/C/F/TAF at week 52 (late switch arm,
44 weeks of D/C/F/TAF exposure) in an extension phase until week 96,
with study visits every 12 weeks. After week 96 participants were given
the opportunity to remain in the trial until the study drug became
commercially available.
2.2. Study endpoints
The primary endpoint was protocol-defined virologic rebound
(PDVR), defined as the proportion of patients with confirmed VL≥50
copies/mL or premature discontinuations irrespective of reason with
last VL≥50 copies/mL, cumulative through week 48 in each arm.
Secondary efficacy endpoints were cumulative PDVR from baseline
through week 96 in the D/C/F/TAF arm and cumulative PDVR from
week 52 through week 96 in the late switch arm, and virologic outcome
at week 96 (VL < 50 and≥50 copies/mL [VF]; FDA-snapshot ana-
lysis) in all randomized participants in the D/C/F/TAF arm and based
on only those who switched in the boosted PI arm, comprising 44 weeks
of D/C/F/TAF exposure. Efficacy endpoints were also evaluated at the
200 copies/mL cutoff.
Other secondary endpoints included change in CD4+ cell count,
post-baseline HIV-1 genotypic resistance (GenoSure MG) in PDVRs with
VL≥ 400 copies/mL at failure (preferably at confirmed rebound), at
later post-rebound time points or at discontinuation, adherence to
treatment based on drug accountability, adverse event (AE) incidences,
changes in serum creatinine, estimated glomerular filtration rate based
on serum creatinine (eGFRcr, Chronic Kidney Disease Epidemiology
Collaboration [CKD-EPI] [Laterza et al., 2002]) and eGFR based on
cystatin C (eGFRcyst, CKD-EPI formula [Laterza et al., 2002; Levey et al.,
2009]), and ratios of total urine protein, urine albumin, retinol binding
protein, and β-2-microglobulin to creatinine (UPCR, UACR, RPB:Cr and
B2M:Cr, respectively). Retrospectively, HIV-1 proviral DNA was se-
quenced from baseline samples (VL < 50 copies/mL) to assess the
Fig. 1. Patient disposition for EMERALD through 96 weeks.
Abbreviations
AE adverse event
ART antiretroviral treatment
BMD bone mineral density
bPI boosted protease inhibitor
CI confidence interval
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration
D/C/F/TAF darunavir/cobicistat/emtricitabine/tenofovir alafena-
mide
DRV darunavir
F/TDF emtricitabine/tenofovir-disoproxil-fumarate
N(t)RTI nucleoside(tide) analog reverse transcriptase inhibitor
PDVR protocol-defined virologic rebound
PI protease inhibitor
RAM resistance-associated mutation
STR single-tablet HIV-1 treatment regimen
VF virologic failure
VL viral load
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prevalence of archived RAMs in patients with prior VF.
Endpoints in the bone investigation substudy were percentage
change in hip, lumbar spine, and femoral neck bone mineral density
(BMD) measured by DXA scans, changes in associated T-score (normal
BMD defined as a T-score≥−1; osteopenia as a T-score from ≥ −2.5
to < −1; and osteoporosis as a T-score < −2.5), and changes in bone
biomarkers.
2.3. Statistical analysis
The main outcome analysis for the D/C/F/TAF arm was based on
the intent-to-treat population, which included all randomized patients
who received at least 1 dose of study drug. For the control arm, the
week 96 analysis was based on patients who switched at week 52. A
per-protocol analysis was also performed, which excluded patients with
major protocol violations or other predefined criteria that potentially
affected the efficacy outcome (Supplementary Table 1).
Data analysis was performed using SAS software (SAS Institute, Inc,
Cary, NC, USA) version 9.2. Least squares mean change from reference
in CD4+ cell count (non-completer equaled failure; last observation was
carried forward otherwise) and associated 95% confidence intervals
(CIs) were evaluated with ANCOVA, including a term for bPI used at
screening and reference CD4+ count value as a covariate, fit separately
for each treatment arm. Within treatment arm comparisons for change
at week 96 from reference were assessed by Wilcoxon signed-rank test
for eGFR, renal biomarkers and fasting lipids and by paired t-test for
BMD. Reference for the D/C/F/TAF arm was baseline. Reference for the
late switch arm was the last value before the switch.
3. Results
3.1. Patient baseline characteristics and disposition
Overall (N= 1141) demographic and disease characteristics at
baseline have been previously described (Orkin et al., 2018)
(Supplementary Table 2). Median age was 46 years and most were male
(82%), white (75%), and receiving boosted DRV (70%) at screening.
Median (IQR) time since HIV diagnosis was 9.3 (4.2–18.1) years.
Overall, previous ART (including screening ART and PI booster counted
as a separate antiretroviral) included: ≥8 antiretrovirals (27% [312/
1141]); ≥5 antiretrovirals (58%), ≥2 PIs (41%), ≥3N(t)RTIs (42%),
≥1 non-nucleoside reverse transcriptase inhibitor (NNRTI) (30%), and
≥1 integrase inhibitor (6%). Overall, 169 (15%) patients had previous
antiretroviral VF (7% on a PI, 11% on an N(t)RTI, 6% on an NNRTI, and
1% on an integrase inhibitor).
Of 1141 patients randomized and treated, 1087/1141 patients
(95%) completed 48 weeks, and 1080 patients (95%) continued in the
extension phase (N=728 D/C/F/TAF [95%]; N=352 late switch
[93%]) with 1036 patients (91%) ongoing on study treatment through
96 weeks (Fig. 1). From week 48 through 96 weeks, the most common
reasons for discontinuation, as indicated by the investigator, were AEs,
loss to follow-up and withdrawn consent (Fig. 1) with a similar
Fig. 2. Protocol-defined virologic rebound (PDVR) through Week 96; A) ≥50 copies/mL and B) ≥200 copies/mL.
*Two-sided Exact Clopper-Pearson 95% confidence interval (CI); †Comprising 44 weeks of D/C/F/TAF exposure.
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proportion between arms (4%).
3.2. Efficacy analyses
Few patients had PDVR (VL≥50 copies/mL) cumulative through
week 96 in the D/C/F/TAF arm (3.1%, 24/763) (Fig. 2A). In the late
switch arm, PDVR occurred in 2.3% of patients (8/352) from week 52
through week 96 (Fig. 2A). Of the patients with PDVR, 14/24 in the D/
C/F/TAF arm through week 96 and 2/8 in the late switch arm from
week 52 through week 96 resuppressed by week 96 while maintaining
D/C/F/TAF therapy (Fig. 2A). There were 4/763 (0.5%) PDVRs
(VL≥ 200 copies/mL) in the D/C/F/TAF arm cumulative through week
96 and 2/352 (0.6%) over 44 weeks in the late switch arm (Fig. 2B).
PDVR (VL≥50 copies/mL) cumulative through week 96 was con-
sistent using the per-protocol analysis (Supplementary Table 3).
Through 96 weeks, no patient in the D/C/F/TAF arm discontinued
dosing due to loss of virologic efficacy.
At week 96, VL≥ 50 copies/mL (FDA-snapshot analysis) occurred
in 9/763 (1.2%) patients in the D/C/F/TAF arm and in 6/352 (1.7%)
patients in the late switch arm (Fig. 3A and Supplementary Table 4). A
high proportion of patients in the D/C/F/TAF arm (90.7%, 692/763)
and late switch arm (93.8%, 330/352) had a VL < 50 copies/mL (FDA-
snapshot analysis) at week 96 (Fig. 3A and Supplementary Table 4). Of
those who were<50 copies/mL at week 48, 95.2% (689/724) (D/C/F/
TAF arm) and 93.7% (328/350) (late switch arm) maintained virologic
suppression at week 96. Virologic responses were consistent with the
FDA-snapshot analysis using the VL < 200 copies/mL cutoff (Fig. 3B
and Supplementary Table 4) and the per-protocol< 50 copies/mL FDA-
snapshot analysis (Supplementary Table 3).
PDVR and FDA-snapshot outcomes were consistent across the
baseline patient subgroups, sex, age, race, previous antiretroviral use,
and previous antiretroviral VF (Supplementary Table 5). In the D/C/F/
TAF arm, of the 116 patients with ≥1 previous antiretroviral VF, PDVR
occurred in 4.3% of patients (5/116) and 87.1% (101/116) were
suppressed (VL < 50 copies/mL; FDA-snapshot analysis) at week 96.
3.3. Immunologic response
The least squares mean (95% CI) increase from baseline in CD4+
cell count to week 96 was 32.1 (95% CI: 16.4 to 47.8) cells/mm3 in the
D/C/F/TAF arm. In the late switch arm, the increase from the last value
prior to switch to week 96 was 13.1 (95% CI: -8.0 to 34.1) cells/mm3.
3.4. Resistance analysis
Few patients had PDVR cumulative through 96 weeks, with most
having low VL values throughout the study, so very few samples were
eligible for genotyping (HIV-1 RNA≥400 copies/mL at rebound or at
later time points). Through week 96, 4 out of 24 rebounders in the D/C/
F/TAF arm had post-baseline genotype data, and 2 out of 8 rebounders
in the late switch arm had genotype data after week 52. No DRV, pri-
mary PI, tenofovir or emtricitabine RAMs (Wensing et al., 2014) were
observed post baseline. All patients had HIV-1 virus susceptible to all
drugs in the regimens. One patient in the D/C/F/TAF arm had a sec-
ondary PI RAM L63P and an NNRTI RAM K103N, conferring resistance
to efavirenz (EFV) and nevirapine, which was probably related to
previous virologic failure of EFV/F/TDF and previous use of nevirapine.
3.5. Adherence to treatment
Median (IQR) cumulative adherence to the end of week 96, as
measured by pill count, was 99.7% (98.2%; 100.2%) in patients in the
D/C/F/TAF arm. Median (IQR) cumulative adherence was 99.2%
(96.9%; 100.0%) from baseline to week 52 and 99.7% (97.4%, 100.0%)
from week 52 to week 96 in the late switch arm.
Fig. 3. FDA-snapshot analysis at weeks 48 and 96;
A) < 50 copies/mL and B) < 200 copies/mL.
*Two-sided Exact Clopper-Pearson 95% confidence
interval (CI); †Last VL in week 48 or week 96
window ≥ 50 copies/mL, or discontinuation for ef-
ficacy reasons, or premature discontinuations (not
due to efficacy, adverse events or death), with last
(single) VL ≥ 50 copies/mL; ‡Last VL in week 48 or
week 96 window ≥ 200 copies/mL, or discontinua-
tion for efficacy reasons, or premature discontinua-
tions (not due to efficacy, adverse events or death),
with last (single) VL ≥ 200 copies/mL; §Late switch
to D/C/F/TAF arm week 96 results are based on
patients who switched to D/C/F/TAF at week 52
(comprising 44 weeks of D/C/F/TAF exposure).
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3.6. Safety and tolerability
D/C/F/TAF was well tolerated with 9% [66/763] serious AEs and
2% [17/763] AE-related discontinuations through 96 weeks in the D/
C/F/TAF arm of which 5% (36/728) and 1% (5/728), respectively,
occurred between weeks 48 and 96. In the late switch arm from week
52 through week 96, 6% [21/352] and 2% [7/352]) serious AEs and
AE-related discontinuations occurred (Table 1). AEs at least possibly
related to study drug were reported in 22% [165/763] of patients in the
D/C/F/TAF arm over 96 weeks, and in 11% [38/352] of patients over
44 weeks of D/C/F/TAF treatment in the late switch arm. The most
common AEs (all grades, ≥ 5% in both D/C/F/TAF and late switch
arms) through week 96 were upper respiratory tract infection, viral
upper respiratory tract infection, diarrhea and headache.
Most AEs, irrespective of causality, were grade 1 or 2. The most
common grade 3 AE in the D/C/F/TAF arm was increased low-density
lipoprotein-cholesterol (LDL-C), which was reported for 2 patients be-
fore week 48 and 2 patients after week 48 (both < 1%), and in the late
switch arm from week 52 through week 96, pneumonia, tendon rup-
ture, hypercholesterolemia, and depression, each reported for 2 pa-
tients (< 1%). Three cases of myocardial infarction (0.3%, 3/1080)
occurred after week 48, including 2 in the D/C/F/TAF arm and 1 in the
late switch arm.
Three deaths occurring after week 48 in the D/C/F/TAF arm were
Table 1
Overview of treatment-emergent AEs and laboratory abnormalities and median (IQR) change from baseline in lipids at Week 96.
D/C/F/TAF Arm Late Switch Arm
D/C/F/TAF
(baseline – week 48)
N=763
D/C/F/TAF (week
48 – week 96)
N=728
D/C/F/TAF
(baseline – week 96)
N=763
P-valueb,c bPI + F/TDF (baseline –
week 52) N = 378
D/C/F/TAFa (week
52 –week 96)
N=352
P-valueb,c
Patient years exposured 689 664 1353 366 295
Treatment-emergent AEs, n (%)
AEs, any grade, regardless of
causality
630 (83) 522 (72) 690 (90) ND 316 (84) 258 (73) ND
Study drug-related AEs 144 (19) 37 (5) 165 (22) ND 28 (7) 38 (11) ND
Grade 3–4 AEs regardless of
causality
54 (7) 52 (7) 98 (13) ND 31 (8) 26 (7) ND
Study drug-related Grade 3 or 4
AEs
10 (1) 6 (1) 14 (2) ND 4 (1) 7 (2) ND
Serious AEs regardless of causality 35 (5) 36 (5) 66 (9) ND 18 (5) 21 (6) ND
Study drug-related serious AEs 1 (< 1) 1 (< 1) 2 (< 1) ND 0 1 (< 1) ND
AE-related discontinuations 12 (2) 5 (1) 17e (2) ND 5 (1) 7e (2) ND
Deaths 0 3f (< 1) 3f (< 1) ND 0 0 ND
Most common AEs regardless of causality (≥10% D/C/F/TAF arm through 96 weeks)
Upper respiratory tract infection 81 (11) 60 (8) 122 (16) ND 39 (10) 30 (9) ND
Viral upper respiratory tract
infection
72 (9) 34 (5) 98 (13) ND 40 (11) 25 (7) ND
Diarrhea 60 (8) 26 (4) 80 (11) ND 18 (5) 16 (5) ND
Headache 58 (8) 25 (3) 79 (10) ND 18 (5) 18 (5) ND
Back pain 55 (7) 29 (4) 76 (10) ND 23 (6) 12 (3) ND
Study drug-related AEs (all grades; ≥ 1% either arm)
Diarrhea 16 (2) 1 (< 1) 17 (2) ND 2 (1) 4 (1) ND
Headache 10 (1) 1 (< 1) 11 (1) ND 0 1 (< 1) ND
Abdominal pain 11 (1) 0 11 (1) ND 0 0 ND
Osteopenia 5 (1) 0 5 (1) ND 9 (2) 0 ND
Most common treatment-emergent grade 3 or 4 laboratory abnormalities (> 5% either arm)
Fasting LDL-C (≥4.90mol/L; ≥
190mg/dL)
47/737 (6) 38/688 (6) 67/741 (9) ND 6/364 (2) 9/328 (3) ND
Fasting total cholesterol
(≥7.77mol/L; ≥ 300mg/dL)
27/737 (4) 16/692 (2) 36/741 (5) ND 5/364 (1) 6/330 (2) ND
Median (IQR) change in fasting lipids
TC (mg/dL) +19.9 (1.2; 39.4) ND +22.0 (−0.4; 44.0) < 0.001 +1.3 (−12.0; 20.0) +22.0 (3.0; 42.7) <0.001
HDL-C (mg/dL) +2.7 (−3.0; 8.0) ND +3.0 (−2.0; 8.5) < 0.001 0.0 (−4.6; 4.0) +3.3 (−2.0; 8.0) < 0.001
LDL-C (mg/dL) +15.9 (0.0; 32.0) ND +17.0 (−3.0; 35.2) < 0.001 +1.9 (−12.0; 17.0) +15.0 (0.0; 32.9) <0.001
Triglycerides (mg/dL) +5.7 (−21.0; 39.0) ND +7.0 (−25.0; 43.0) < 0.001 +4.9 (−23.0; 39.0) +8.0 (−25.8;
47.0)
0.004
TC/HDL-C ratio +0.20 (−0.20;
0.60)
ND +0.20 (−0.40;
0.70)
< 0.001 +0.10 (−0.30; 0.40) +0.20 (−0.30;
0.70)
<0.001
AEs, adverse events; IQR, interquartile range; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; ND, not
determined.
a Comprising 44 weeks of D/C/F/TAF exposure (i.e. from the switch to D/C/F/TAF at week 52).
b Within treatment arm comparisons for change at week 96 from reference assessed by: Wilcoxon signed-rank test (eGFR, renal biomarkers and fasting lipids) and
paired t-test (BMD).
c Reference for the D/C/F/TAF arm is study baseline and for the late switchers is the last value before the switch.
d Patient years of exposure= sum of treatment duration (in weeks) x 7/365.25.
e D/C/F/TAF arm: abdominal pain, diarrhea, gastrooesophageal reflux disease, pancreatitis, alanine aminotransferase increased, blood corticotrophin decreased,
cortisol decreased, Hodgkin's disease, lymphoma, anxiety, depression suicidal, insomnia, Cushing's syndrome, edema peripheral, headache, urticaria, flushing (n=1
each); myocardial infarction (n= 2), chronic kidney disease (n= 2; worsening of pre-existing chronic kidney disease in one patient prior to week 48 (Orkin et al.,
2018) and chronic kidney disease in a participant after week 48); D/C/F/TAF late switch arm: vertigo, Cushing's syndrome, diarrhea, nausea, vomiting, malaria,
pregnancy, depression, rash (n=1 each).
f Three deaths were due to metastatic pancreatic carcinoma and 2 cases of myocardial infarction, 1 of which was in a patient who was a smoker, with an ongoing
medical history of hyperlipidemia and hypertension and 1 was in a patient with an ongoing medical history of obesity and hypertension.
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due to metastatic pancreatic carcinoma and 2 cases of myocardial in-
farction; 1 in a patient who was a smoker with an ongoing medical
history of hyperlipidemia and hypertension and 1 patient with an on-
going medical history of obesity and hypertension. The only other
serious AE deemed as possibly related to a study drug by the in-
vestigator and occurring after week 48 was grade 3 Cushing's syndrome
in the late switch arm, which is likely explained by the administration
of intramuscular corticosteroid injections.
Renal AEs regardless of causality occurred in 3% (20/763) of pa-
tients in the D/C/F/TAF arm over 96 weeks, and in 1% [5/352] of
patients in the late switch arm from week 52 through week 96. Two
grade 2, non-serious, related renal AEs led to discontinuation in the D/
C/F/TAF arm over 96 weeks (Table 1 footnote). Neither renal AE met
the criteria for proximal renal tubulopathy (PRT). No renal AEs led to
discontinuation of D/C/F/TAF in the late switch arm or suggested
treatment-emergent PRT.
Most treatment-emergent laboratory abnormality events were grade
1 or 2. Only grade 3 or 4 fasting LDL-C occurred in ≥5% of patients in
the D/C/F/TAF arm over 96 weeks (9% [67/741]) (Table 1) of which
6% (38/688) occurred after week 48. No events occurred in ≥5% of
patients in the late switch arm.
Median (IQR) change in body weight at week 96 was +1.8 (−0.8;
4.6) kg versus baseline in the D/C/F/TAF arm and +1.6 (−0.4; 3.5) kg
versus the value prior to switching in the late switch arm.
3.6.1. Laboratory parameters
Fasting lipid parameters remained stable after week 48 in the D/C/
F/TAF arm and increased from the value prior to switching to week 96
in the late switch arm. The change in TC/HDL-C ratio from the value
prior to switching in the late switch arm was +0.20, while the ratio in
the D/C/F/TAF arm remained stable after week 48 (all changes
P < 0.005) (Table 1 and Supplementary Fig. 1). During treatment,
lipid-lowering drugs were started by 32/763 (4%) and 59/763 (8%) of
patients by weeks 48 and 96, respectively, in the D/C/F/TAF arm, and
by 3% (11/378) and 5% (19/352), respectively, in the control arm.
In the D/C/F/TAF arm, median (IQR) change from baseline to week
96 in eGFRcr was −1.3 (−8.3; 5.1) mL/min/1.73m2 (Fig. 4A)
(P < 0.001). Median change from the value prior to switching to week
96 in eGFRcr was −0.7 (−6.9; 4.9) mL/min/1.73m2 in the late switch
arm (P=0.007) (Fig. 4A). Median changes in eGFRcyst were similar
(Fig. 4B).
In the D/C/F/TAF arm, improvements in renal biomarkers seen at
48 weeks compared with baseline were maintained through week 96
(Supplementary Fig. 2A). Median (IQR) changes from baseline to week
Fig. 4. Change from reference to week 48 and week 96 in renal and bone parameters. A) eGFRcyst, B) eGFRcr and BMD of the C) hip, D) lumbar spine, and E) femoral
neck.
*Comprising ~44 weeks of D/C/F/TAF exposure (i.e. from the switch to D/C/F/TAF at week 52). †Within treatment arm change from reference assessed by Wilcoxon
signed-rank test (eGFR) and paired t-test (BMD). ‡Reference for D/C/F/TAF and control is baseline and for late switch (D/C/F/TAF) is the last value before the
switch.
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96 were −22.2 (−51.5; −3.5) mg/g for UPCR, −0.6 (−3.7; 1.2) mg/g
for UACR, −25.1 (−106.4; 13.1) μg/g for RBP:Cr and −68.2 (−386.6;
−11.0) μg/g for B2M:Cr (all P < 0.001 vs. baseline). In the late switch
arm, significant improvements at week 96 versus the value prior to
switching (all P < 0.001) were seen for median (IQR) changes in UPCR
[–12.8 (−48.2; 6.4) mg/g], UACR [–0.9 (−6.0; 1.1) mg/g], RBP:Cr
[–39.1 (−200.1; 4.3) μg/g] and B2M:Cr [–110.3 (−496.8; −18.3) μg/
g] (Supplementary Fig. 2A).
3.6.2. Bone substudy
The bone substudy included 209 patients in the D/C/F/TAF arm and
108 in the control arm (Orkin et al., 2018). Over 96 weeks, there were
sustained improvements in BMD at the hip (+1.85% at week 96 vs.
baseline; Fig. 4C), lumbar spine (+2.00%; Fig. 4D), and femoral neck
(+1.38%; Fig. 4E) in the D/C/F/TAF arm (all P < 0.001 vs. baseline,
paired t-test). Similar significant improvements in BMD at week 96
compared with the value prior to switching were seen in the late switch
arm (Fig. 4C‒E).
In the D/C/F/TAF arm, the proportion of patients who had a ≥3%
decrease or increase in hip, lumbar spine, and femoral neck BMD at
week 96 versus baseline was stable through week 96 (Supplementary
Table 6). In the late switch arm, more patients had a ≥3% increase in
BMD at each site over 44 weeks of D/C/F/TAF treatment than over the
first 48 weeks of bPI plus F/TDF therapy, and fewer patients had a
≥3% decrease in BMD (Supplementary Table 6). Conclusions were si-
milar for increases or decreases of ≥5% or ≥7% in BMD, as well for the
proportions of patients with an improvement (osteopenia to normal or
osteoporosis to normal or osteopenia) or a decline (normal to osteo-
penia or normal or osteopenia to osteoporosis) in BMD clinical status
(Supplementary Table 6).
Changes in bone biomarkers overs weeks 52–96 in the late switch
arm were similar to those reported by week 48 in the D/C/F/TAF arm
(Supplementary Fig. 2B).
4. Discussion
The week 96 analysis of this phase 3, randomized, open-label trial
showed that a low proportion of treatment-experienced, virologically
suppressed HIV-1-positive adults in the D/C/F/TAF arm had PDVR
(≥50 copies/mL) cumulative through 96 weeks (3.1%) and a high
proportion (90.7%) remained suppressed (VL < 50 copies/mL) at
week 96, with few patients (1.2%) having VL≥50 copies/mL (FDA-
snapshot analysis). Virologic rebound mainly consisted of low-level and
transient viremia, with very few PDVRs ≥200 copies/mL (0.5%). More
than half of patients in the D/C/F/TAF arm with PDVR ≥50 copies/mL
achieved resuppression by week 96, without a change in therapy. In the
late switch arm, only 2.3% had PDVR cumulative through 44 weeks,
and virologic suppression was also sustained at week 96 (93.8%) with
1.7% of patients having VL≥50 copies/mL (FDA snapshot), consistent
with week 48 results in the D/C/F/TAF arm. Importantly, through week
96 no patients needed to discontinue D/C/F/TAF due to lack of efficacy.
Results were consistent across baseline patient subgroups, in the per-
protocol PDVR and FDA-snapshot analyses and using the 200 copies/
mL cutoff.
While considering differences in study designs when making com-
parisons, entry criteria were less restrictive than in other switch studies
with comparable or lower response rates e.g. for bictegravir (Daar et al.,
2018; Molina et al., 2018), dolutegravir (Joly et al., 2017; Llibre et al.,
2018; Taiwo et al., 2018; Trottier et al., 2017), and atazanavir (Di
Giambenedetto et al., 2017; Perez-Molina et al., 2015). In EMERALD,
there was no exclusion based on previous VF or RAMs, except for his-
tory of VF on DRV-based regimens or DRV RAMs if historical genotypes
were available. However, it should be noted only ≥3 DRV RAMs is
correlated with DRV resistance (de Meyer et al., 2008). N(t)RTI RAMs,
including emtricitabine or tenofovir RAMs, were not an exclusion cri-
terion. The proportion of patients achieving VL < 50 copies/mL at 96
weeks was similar to week 96 response rates in other HIV studies
evaluating switching to integrase inhibitor-based regimens (Aboud
et al., 2018; Gatell et al., 2019).
PDVR and response rates should be placed in the context that these
patients were treatment experienced, with 58% of patients having re-
ceived ≥5 previous antiretroviral agents, and 15% having previous
antiretroviral VF. Previous antiretroviral use and VF did not affect
PDVR and response rates.
No patient developed resistance to any of the study drugs through
week 96 despite a cumulative 1648 patient-years of exposure to D/C/F/
TAF. This is consistent with previous DRV and D/C/F/TAF studies
(Eron et al., 2018; Lathouwers et al., 2017), further supporting the high
genetic barrier to resistance of DRV.
D/C/F/TAF was generally well tolerated through 96 weeks, with
low incidences of discontinuations due to AEs (2%) that were numeri-
cally lower than incidences seen in integrase inhibitor-based regimen
switching studies over 96 weeks (Aboud et al., 2018; Gatell et al.,
2019). The D/C/F/TAF tolerability profile at week 96 was consistent
with the week 48 analyses of EMERALD (Orkin et al., 2018) and
AMBER (Eron et al., 2018).
The small increase in body weight in the D/C/F/TAF arm over 2
years (1.8 kg) is consistent with previous studies of patients receiving
ART (Taramasso et al., 2017), and may be due in part to lifestyle
changes and improved disease control. Weight gains were numerically
larger over 9–18 months when switching to integrase inhibitor-based
ART, particularly for dolutegravir (Menard et al., 2017; Norwood et al.,
2017).
Renal, bone, and lipid safety were consistent with the established
effects of TAF versus TDF and cobicistat (DeJesus et al., 2018; Eron
et al., 2018; Orkin et al., 2018; Raffi et al., 2017; Wohl et al., 2016).
Small decreases in eGFRcr in both arms were well within normal limits
and possibly due to the effect of cobicistat on inhibition of tubular se-
cretion of creatinine without reducing actual GFR (Elion et al., 2011;
Gallant et al., 2013; German et al., 2012). When measuring GFR with
cystatin C, which is not affected by the interaction of cobicistat with
creatinine secretion (Laterza et al., 2002), changes were also small,
with all results remaining within normal limits.
Improvements in renal tubular proteinuria and bone parameters
were maintained in the D/C/F/TAF arm and seen in the late switch arm
from week 52 to week 96, suggesting that D/C/F/TAF has a lower
potential for nephrotoxicity and bone loss than the control regimen.
These renal tubular proteinuria and bone safety results are consistent
with the week 48 results in the D/C/F/TAF arm of EMERALD (Orkin
et al., 2018) and AMBER (Eron et al., 2018) and week 96 analyses of
previous phase 3 studies in virologically suppressed patients who
switched from a TDF- to a TAF-containing regimen (DeJesus et al.,
2018; Raffi et al., 2017; Wohl et al., 2016), including a pooled analysis
of 5 phase 3 studies (Rockstroh et al., 2017).
In the D/C/F/TAF arm, fasting lipid levels remained stable after
week 48 with minimal increases in the late switch arm and an identical
change in TC/HDL-C ratio (+0.2) in both arms at week 96. Only a small
proportion of patients initiated lipid-lowering therapy in both arms.
A study limitation was the lack of a control arm in the week 96
analysis, as patients in both arms were switched to D/C/F/TAF. Other
limitations, as at week 48, include the lack of power to assess efficacy in
patient subgroups and assessment of bone parameters in only a subset
of participants.
In conclusion, in virologically suppressed, treatment-experienced,
HIV-positive adults, including those with prior VF and archived re-
sistance, switching to the D/C/F/TAF STR resulted in low PDVR rates
cumulative through 96 weeks (3% D/C/F/TAF; 2% late switch) and
maintenance of high virologic suppression rates (> 90%) at week 96.
Efficacy and safety results in the late switch arm were consistent with
week 48 results in the D/C/F/TAF arm. No patients discontinued for
efficacy-related reasons, and no drug resistance mutations developed.
D/C/F/TAF was well tolerated over 96 weeks with bone, renal and lipid
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safety consistent with known profiles of the D/C/F/TAF components.
Results of EMERALD through 96 weeks confirm the efficacy, high ge-
netic barrier to resistance and safety advantages of D/C/F/TAF, even in
patients with a history of non-DRV VF.
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